Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2013 Dec;33(12):1026-33.

doi: 10.1016/j.nutres.2013.08.009. Epub 2013 Sep 18.

Heather L Hutchins-Wiese, Anne M Kenny, Stephen J Walsh, Robin H Abourizk, Richard S Bruno, Rosanne Lipcius, Pamela Fall, Alison Kleppinger, Lisa Kenyon-Pesce, Karen M Prestwood, Jane E Kerstetter

Affiliations

Randomized Controlled Trial

Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial

Kelsey M Mangano et al. Nutr Res. 2013 Dec.

Abstract

Soy foods contain several components, notably, isoflavones and amino acids, that may improve cardiovascular health. We evaluated the long-term effect of soy protein and/or soy isoflavones supplementation on serum lipids and inflammatory markers using a 1-year randomized, double-blind, placebo-control, clinical trial in 131 healthy ambulatory women older than 60 years. We hypothesized that soy protein, in combination with isoflavones, would have the largest positive effect on coronary heart disease risk factors (serum lipids and inflammatory markers) compared with either intervention alone and that, within groups receiving isoflavones, equol producers would have more positive effects on coronary heart disease risk factors than nonequol producers. After a 1-month baseline period, participants were randomized into 1 of 4 intervention groups: soy protein (18 g/d) and isoflavone tablets (105 mg/d isoflavone aglycone equivalents), soy protein and placebo tablets, control protein and isoflavone tablets, or control protein and placebo tablets. T Tests were used to assess differences between equol and nonequol producers. Ninety-seven women completed the trial. Consumption of protein powder and isoflavone tablets did not differ among groups, and compliance with study powder and tablets was 79% and 90%, respectively. After 1 year, in the entire population, there were either no or little effects on serum lipids and inflammatory markers, regardless of treatment group. Equol producers, when analyzed separately, had significant improvements in total cholesterol/high-density lipoprotein and low-density lipoprotein/high-density lipoprotein ratios (-5.9%, P = .02; -7.2%, P = .04 respectively). Soy protein and isoflavone (either alone or together) did not impact serum lipids or inflammatory markers. Therefore, they should not be considered an effective intervention to prevent cardiovascular disease because of lipid modification in healthy late postmenopausal women lacking the ability to produce equol.

Keywords: ANOVA; BMI; CHD; CVD; Cardiovascular health; Equol producer; HDL; IL-6; LDL; Postmenopausal women; Serum lipids; Soy isoflavones; Soy protein; TC; TG; analysis of variance; body mass index; cardiovascular disease; coronary heart disease; high-density lipoprotein; high-sensitivity C-reactive protein; hsCRP; interleukin-6; low-density lipoprotein; total cholesterol; triglycerides.

© 2013 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

None of the authors have a conflict of interest.

Figures

Fig

Fig

Values are percent change of ratios of lipids in serum between equol (n = 25) and nonequol (n = 26) producers in those who received isoflavone supplementation, as assessed by independent t test (error bars are ±SEM). The ratios of serum lipids in closed boxes are TC/HDL cholesterol, and those in the open boxes are LDL cholesterol/HDL cholesterol. Independent t test analyses were used to assess differences between equol and nonequol producers. *P = .018 for percent change in the TC/HDL ratio between equol and nonequol producers. #P = .043 for percent change in the LDL/HDL ratio between equol and nonequol producers.

References

    1. Xu DLHaJ. National Vital Statistics Reports. US Department of Health and Human Services; 2012. Deaths: Preliminary Data for 2011. - PubMed
    1. Woodard GA, Brooks MM, Barinas-Mitchell E, Mackey RH, Matthews KA, Sutton-Tyrrell K. Lipids, menopause, and early atherosclerosis in Study of Women’s Health Across the Nation Heart women. Menopause. 2011;18:376–84. - PMC - PubMed
    1. Munro IC, Harwood M, Hlywka JJ, Stephen AM, Doull J, Flamm WG, et al. Soy isoflavones: a safety review. Nutr Rev. 2003;61:1–33. - PubMed
    1. Vitale DC, Piazza C, Melilli B, Drago F, Salomone S. Isoflavones: estrogenic activity, biological effect and bioavailability. Eur J Drug Metab Pharmacokinet. 2013;38(1):15–25. - PubMed
    1. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 2005;230:155–70. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources